2021
Adoption of New Risk Stratification Technologies Within US Hospital Referral Regions and Association With Prostate Cancer Management
Leapman MS, Wang R, Park HS, Yu JB, Sprenkle PC, Dinan MA, Ma X, Gross CP. Adoption of New Risk Stratification Technologies Within US Hospital Referral Regions and Association With Prostate Cancer Management. JAMA Network Open 2021, 4: e2128646. PMID: 34623406, PMCID: PMC8501394, DOI: 10.1001/jamanetworkopen.2021.28646.Peer-Reviewed Original ResearchConceptsProstate magnetic resonance imagingMagnetic resonance imagingHospital referral regionsProportion of patientsProstate cancerGenomic testingCohort studyReferral regionsRetrospective cohort studyProstate cancer carePatient-level analysisCommercial insurance claimsProstate cancer managementUS hospital referral regionsYears of ageProportion of menPatients 40Definitive treatmentCancer careTesting uptakeHRR levelMAIN OUTCOMECancer managementPatientsRegional uptake
2019
Conservative management of low‐risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database
Mahal A, Butler S, Franco I, Muralidhar V, Larios D, Pike L, Zhao S, Sanford N, Dess R, Feng F, D’Amico A, Spratt D, Yu J, Nguyen P, Rebbeck T, Mahal B. Conservative management of low‐risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database. Cancer 2019, 125: 3338-3346. PMID: 31251398, DOI: 10.1002/cncr.32332.Peer-Reviewed Original ResearchConceptsLow-risk prostate cancerPositive biopsy coresShort-term outcomesBiopsy coresProstate cancerManagement of low-risk prostate cancerOlder patientsProstate cancer-specific mortality ratesConservative managementProstate cancer-specific mortalityCancer-specific mortality ratesActive surveillance/watchful waitingRate of conservative managementOlder menCancer-specific mortalityShort-term safetyQuality-of-life implicationsDefinitive treatmentYounger patientsOverall mortalityPatientsMortality rateProstateNational databaseCancer
2016
Weighing Risk of Cardiovascular Mortality Against Potential Benefit of Hormonal Therapy in Intermediate-Risk Prostate Cancer
Lester-Coll N, Johnson S, Magnuson W, Goldhaber S, Sher D, D'Amico A, Yu J. Weighing Risk of Cardiovascular Mortality Against Potential Benefit of Hormonal Therapy in Intermediate-Risk Prostate Cancer. Journal Of The National Cancer Institute 2016, 109: djw281. PMID: 28040795, DOI: 10.1093/jnci/djw281.Peer-Reviewed Original ResearchConceptsIntermediate-risk prostate cancerQuality-adjusted life yearsHormone therapyHistory of myocardial infarctionCardiac risk factorsBiochemical failureProstate cancerRadiation therapyCardiac riskProbability of biochemical failureMonths of hormone therapyRisk factorsMyocardial infarctionYears of follow-upBenefits of HTRisk of cardiovascular mortalityDisease recurrence riskCardiac risk groupsComparing quality-adjusted life-yearsYoung menRecurrence riskFollow-upRisk groupsCardiovascular mortalityLow riskDisparities in Treatment of Patients With High-risk Prostate Cancer: Results From a Population-based Cohort
Wang E, Yu J, Abouassally R, Meropol N, Cooper G, Shah N, Williams S, Gonzalez C, Smaldone M, Kutikov A, Zhu H, Kim S. Disparities in Treatment of Patients With High-risk Prostate Cancer: Results From a Population-based Cohort. Urology 2016, 95: 88-94. PMID: 27318264, DOI: 10.1016/j.urology.2016.06.010.Peer-Reviewed Original ResearchConceptsHigh-risk prostate cancerWatchful waitingRadiation therapyProstate cancerPrimary treatmentTreatment of high-risk prostate cancerOdds ratioNational Cancer Data BaseMultivariate logistic regression analysisTreatment of patientsLogistic regression analysisRadical prostatectomyPrimary therapyCurative therapyPrimary outcomeCancer communityTherapySignificant racial disparitiesAcademic hospitalPatientsBlack menCancerHospitalStudy periodWhite men
2015
Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9?
Mahal B, Muralidhar V, Chen Y, Choueiri T, Hoffman K, Hu J, Sweeney C, Yu J, Feng F, Trinh Q, Nguyen P. Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9? BJU International 2015, 118: 95-101. PMID: 26207642, DOI: 10.1111/bju.13239.Peer-Reviewed Original ResearchConceptsProstate cancer-specific mortalityGleason score 5Risk of prostate cancer-specific mortalityGleason score 4Prostate cancerScore 5Increased risk of PCSMGray competing risk regression analysisProstate cancer-specific mortality outcomesProstate cancer-specific mortality ratesScore 4Competing risk regression analysisGleason score 3Gleason score 8Gleason score 9Primary Gleason patternReference group of patientsCancer-specific mortalityAggressive treatment strategiesGroup of patientsRisk regression analysisHighest-risk patientsGleason 4Gleason scoreGleason pattern